Market Overview

BTIG Sees Limited Upside For Globus Medical, Downgrades To Neutral

Share:
Related
Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Medtronic Steps Up With A Bigger Commitment To Robotics (Seeking Alpha)

Globus Medical Inc (NYSE: GMED) is up 64 percent year-over-year, but it may be exhausting its potential.

The Rating

BTIG analyst Ryan Zimmerman downgraded Globus Medical to Neutral.

The Thesis

Globus Medical is seen to have ridden intensified investor interest in robotics, which compounded strong fundamentals, a positive year in core spine sales, and a good first quarter for robotics commercialization.

BTIG doesn’t necessarily expect the firm to take a turn for the worse.

“We are not saying 1Q18 will miss with our downgrade today either as we believe there may still be early pent-up demand for ExcelsiusGPS in 1Q,” Zimmerman wrote in a Monday note. “In fact, we believe GMED could beat expectations for the quarter.”

He just doesn’t see much upside — perhaps “a dollar or two” — considering overextended valuation relative to the group and the tailwind of robotics growth already baked into the price.

Price Action

Globus Medical fell more than 1 percent on the downgrade, and at time of publication was trading around $50.11.

Related Links:

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

8 Biotech Stocks With Clinical Trial Outcomes In April

Latest Ratings for GMED

DateFirmActionFromTo
Aug 2018Morgan StanleyMaintainsOverweightOverweight
Jun 2018Cantor FitzgeraldInitiates Coverage OnOverweight
May 2018Leerink SwannMaintainsOutperformOutperform

View More Analyst Ratings for GMED
View the Latest Analyst Ratings

Posted-In: btig Ryan ZimmermanAnalyst Color Downgrades Analyst Ratings

 

Related Articles (GMED)

View Comments and Join the Discussion!

DA Davidson Says Its Dropbox Estimates Could Be Conservative: 'We Believe Shares Should Outperform'

Buyer Beware: 5 ETNs To Play The Return Of Market Volatility